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In colorectal cancer (CRC), an internationally standardized mol-
ecular classification has not been implemented yet. Nevertheless,
there are different pathogenetic aspects that could form the basis
for a future molecular classification in CRC (1).
In the classic model, CRC is divided into two major pathways.
The first is the chromosomal instability pathway including 85%
of all CRCs. This pathway is based on the adenoma–carcinoma
sequence, which is defined by consecutive mutations in the APC,
KRAS, and TP53 gene and deletion of the chromosome 18q
(2). An example of an autosomal dominantly inherited disease,
which belongs to the chromosomal instability pathway group, is
the familial adenomatous polyposis syndrome (FAP). The sec-
ond, namely the microsatellite instability pathway (15% of all
CRCs) is defined by a mismatch-repair deficiency, which leads to a
genomic instability. The microsatellite instability status can be spo-
radic (12%) or hereditary (3%, Lynch syndrome-associated CRC,
HNPCC). Sporadic cases can be differentiated from hereditary
cases by using the Amsterdam/Revised Bethesda criteria.
In 2007, Jeremy Jass proposed a molecular classification based
on clinical, morphological, and molecular parameters, which
included five subgroups (3).
Group 1 (12% of all CRCs): chromosomally stable, MLH1
methylated, MSI-H, BRAF mutated, CpG island methylator phe-
notype (CIMP) high status; group 2 (8% of all CRCs): chromo-
somally stable, partially MLH1 methylated, microsatellite stable
(MSS, MSI-L), BRAF mutated, CIMP high; group 3 (20% of all
CRCs): chromosomally instable, MGMT methylated, MSS/MSI-L,
KRAS mutated, CIMP low; group 4 (57% of all CRCs): chro-
mosomally instable, MSS/MSI-L, CIMP negative; group 5 (3% of
all CRCs): chromosomally stable, MSI-H, CIMP negative, BRAF
wild type.
Following up on this last classification, in 2010, Barbara Leggett
and Vicki Whitehall published a pathogenetic overview of sporadic
CRC including three pathways (4).
The serrated pathway: MSI-H, CIMP high, BRAF mutated (cor-
responds to the Jass group 1); the alternative pathway: MSS, CIMP
low, KRAS mutated (corresponds to the Jass group 3; the tradi-
tional pathway: MSS, CIMP negative, BRAT wild type, KRAS wild
type (corresponds to the Jass group 4).
In 2012, the Cancer Genome Atlas Network published a
promising approach for a future molecular classification based
on different pathways (5).
Group 1 (wnt and TGF-beta pathway): proliferation, stem
cell, and progenitor phenotype; group 2 (PIK3CA and RTK–RAS
pathway): proliferation, cell survival, translation; group 3 (p53
pathway): proliferation, cell survival. This approach may elucidate
promising target molecules for wnt pathway inhibitors or pro-
teins of the PIK3CA and RTK–RAS pathway such as IGF2, IGFR,
ERBB2, ERBB3, MEK, AKT, and MTOR.
Recently, a new proposal for a molecular classification of CRC
was published by a research group from Oxford based on 906 stage
II and III CRCs (6).
Group 1: MSI-H and/or BRAF mutated; group 2: chromosoma-
lly instable and/or TP53 mutated with KRAS and PIK3Ca wild type
status; group 3: chromosomally instable, KRAS and/or PIK3CA
mutated; TP53 wild type status; group 4: chromosomally stable,
KRAS and/or PIK3CA mutated; TP53 wild type status; group 5:
NRAS mutated; group 6: no mutations; group 7: other.
All these proposals for a CRC molecular classification have
in common that some molecular features such as KRAS, BRAF,
microsatellite status, and CIMP are often included. Nevertheless,
it has to be kept in mind that molecular markers can be prognos-
tic (i.e., BRAF), predictive (i.e., RAS), or both (i.e., microsatellite
status). Therefore, the main aim of the research topic “Toward
a molecular classification of colorectal cancer” was to include
articles that focus on the role of already established (7–13) or
potentially novel and promising molecular biomarkers such as
telomere length (14) or microRNAs (15) and additionally to give
an overview on the molecular pathology of CRC.
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